Clinical Trial Search

Primary: Number of Participants With Major Molecular Response (MMR) Rate at 24 Weeks — 40; 10 Participants — p=0.029

Primary: Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg) — -2.37; -2.46; -1.86 Percentage of HbA1c — p=<0.001

Primary: Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg) — -2.43; -2.58; -1.44 Percentage of HbA1c — p=<0.001

Primary: The Incidence of TA-TMA. — 5; 15 Participants

Primary: Time to Hospital Discharge or "Ready for Discharge" up to Day 28 — 14.0; 14.0 days — p=0.7414

Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 1; 1 Participants

Primary: Investigator Assessed Progression-Free Survival (invPFS) by RECIST Version 1.1 for Rucaparib Versus Chemotherapy (Efficacy Population) — 7.4; 5.7 Months — p=0.0010

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) up to 28 Days After Study Treatment Discontinuation — 527 Participants

Primary: Percentage of Participants With Continuous Complete Remission of Patients Receiving High-dose and Conventional Dose PEG-asparaginase. — 91.6; 90.7 Percentage of…

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious AEs (SAEs) — 119; 17 Participants

Primary: Percentage of MG-ADL Responders During Cycle 1 (C1); Analyzed in the AChR-Ab Seropositive Population — 67.7; 29.7 percentage of patients — p=<0.0001

Primary: Number of Participant Reporting Continuous Complete Switching From Cigarettes to Halo G6 — 8 Participants

Primary: Change From Baseline in Hemoglobin A1c (HbA1c) — -0.63; -0.56 Percentage of HbA1c — p=0.321

Primary: Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies at Day 28 — 309.0; 110.0; 540.0; 239.9 titers

Primary: Progression Free Survival (PFS) as Assessed by Independent Radiological Review — 2.5; 3.4 months — p=0.76